Milademetan in Advanced/Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05012397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Study identification
- NCT ID
- NCT05012397
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Rain Oncology Inc
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Adrenocortical Carcinoma
- Biliary Tract Cancer
- Bladder Urothelial Carcinoma
- Breast Cancer Invasive
- Cervical Cancer
- Cholangiocarcinoma
- Gastric Cancer
- Head and Neck Carcinoma
- Lung Adenocarcinoma
- MDM2 Gene Amplification
- Melanoma
- Non Small Cell Lung Cancer
- Ovarian Carcinoma
- Pancreas Cancer
- Sarcoma
- Solid Tumors
- Stomach Adenocarcinoma
- Testicular Germ Cell Tumor
Interventions
- RAIN-32 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2021
- Primary completion
- Oct 14, 2023
- Completion
- Oct 14, 2023
- Last update posted
- Oct 16, 2024
2021 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University Medical Center | Palo Alto | California | 94305 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02214 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Hematology Oncology Associates of Central NY | Syracuse | New York | 13057 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Sanford Health | Sioux Falls | South Dakota | 57104 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Northwest Medical Specialities | Tacoma | Washington | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05012397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2024 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05012397 live on ClinicalTrials.gov.